Pyoderma gangrenosum (PG) remains a challenging autoinflammatory skin disorder characterized by painful ulcers that are often refractory to standard therapies. Fortunately, recent evidence highlights the potential of Adalimumab for Pyoderma Gangrenosum as a viable long-term treatment option. A 52-week real-world prospective study now provides clinical insights into its safety and efficacy in managing this rare condition.

Researchers conducted a multicenter observational study involving 67 patients to evaluate long-term outcomes. Most participants presented with the ulcerative subtype and faced significant comorbidities such as diabetes or ulcerative colitis. Consequently, the study assessed safety as the primary outcome, focusing specifically on adverse drug reactions (ADRs). The incidence of infections reported as ADRs was 14.9%, while serious infections occurred in 9% of the cohort. Importantly, no new safety concerns emerged during the observation period, suggesting that the treatment is well-tolerated over a full year.

Long-Term Efficacy of Adalimumab for Pyoderma Gangrenosum

The effectiveness of the therapy was measured using the Physician Global Assessment (PGA) and pain scales. Notably, 57.7% of patients achieved a PGA score of 0 or 1 by week 52, signifying complete or near-complete healing of all lesions. Furthermore, more than half of the patients reported a total absence of pain by the end of the study. This outcome is particularly relevant for patients requiring concomitant systemic steroids, as the biologic showed consistent performance across heterogeneous groups.

Another key finding was the stability of the clinical response after treatment discontinuation. Among patients who stopped the medication due to significant symptom improvement, no relapses occurred during the observation period. Therefore, these results strongly support the use of TNF-alpha inhibitors as a standard of care for patients suffering from persistent or complex PG ulcers.

Frequently Asked Questions

How safe is long-term Adalimumab use for PG?

In this 52-week real-world study, the incidence of infections reported as adverse drug reactions was 14.9%. The study found no new safety signals, indicating a safety profile consistent with its established use in other inflammatory conditions.

Can Adalimumab reduce pain associated with Pyoderma Gangrenosum?

Yes, the study demonstrated significant pain relief over time. By week 52, approximately 52.4% of patients achieved a Verbal Rating Scale (VRS) score of 0, meaning they were completely pain-free.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Yamamoto T et al. Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study. Dermatol Ther (Heidelb). 2026 May 10. doi: 10.1007/s13555-026-01772-4. PMID: 42107018.

Yamasaki K et al. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52-week phase 3 open-label study. J Dermatol. 2022;49(5):479-487.

Orfaly VE et al. Pyoderma Gangrenosum: A Review of Clinical Features and Management. Mayo Clin Proc. 2020;95(12):2710-2722.